FDA’s OPQ Chief Tells Generic Drug Makers Its Time To Up Their Quality Game
The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.
You may also be interested in...
US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.
Oncology, neuroscience, and infectious diseases get acting directors as the expansion and renovation of the Office of New Drugs moves into Phase II.
US FDA task force recommends a rating system that purchasers could rely on to reward manufacturers with robust management systems.